Abnova — Interim / Quarterly Report 2017

Aug 18, 2017

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

1

Safe Harbor Notice

The following pages contain projections & estimates of financial information as well as market and product developments for future periods. These projections & estimates are based on information currently available which we believe to be reliable, but they involve risks & uncertainties. Our actual results of operations & financial condition may differ significantly from those contained in the projections & estimates. The projections & estimates should not be interpreted as legally binding commitments, but rather as flexible information subject to change occasionally.

2

Agenda

✓ Company Overview

✓ Q2&H1-2017 Financial Results

✓ Abnova’s Opportunities in Precision Medicine

✓ Q&A

3

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

I. ABNOVA COMPANY PROFILE

4

Abnova Company Profile

==> picture [454 x 234] intentionally omitted <==

==> picture [454 x 234] intentionally omitted <==

==> picture [273 x 364] intentionally omitted <==

5

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

6

Bioreagent Global Distribution Network

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

7

Consolidated Income Statement Q2&H1 2017

													In NT$K
	Q2‘17	%		Q2‘16	%		H1‘17	%		H1‘16	%		H1 YOY
Net Revenue	122,348		100.0%	111,519		100.0%	242,005		100.0%	229,327		100.0%	5.5%
Cost of Revenue	(65,174)		(53.3%)	(60,178)		(54.0%)	(125,725)		(52.0%)	(121,763)		(53.1%)	3.3%
Unrealized Gross Profit on Sales to Associates	(2,190)		(1.8%)				(3,261)		(1.3%)
Gross Profit	54,984		44.9%	51,341		46.0%	113,019		46.7%	107,564		46.9%	5.1%
Operating Expense	(42,750)		(34.9%)	(42,399)		(38.0%)	(82,455)		(34.1%)	(80,606)		(35.1%)	2.3%
Operating Income	12,234		10.0%	8,942		8.0%	30,564		12.6%	26,958		11.8%	13.4%
Non Operating Income	8,098		6.6%	383		0.3%	3,518		1.5%	(407)		(0.2%)	(964.4%)
Income before Tax	20,332		16.6%	9,325		8.4%	34,082		14.1%	26,551		11.6%	28.4%
Income after Tax	17,027		13.9%	13,216		11.9%	28,884		11.9%	27,876		12.2%	3.6%
Basic EPS after Tax	0.29			0.22			0.49			0.47

8

Revenue Breakdown by Product

==> picture [794 x 359] intentionally omitted <==

----- Start of picture text -----

In NT$K 2017 Jan-Jul
500000
16,739
400000 16,661
69,542
66,469 4.5%
16.9%
300000
48,354
200000 38,441 13.5%
65.1%
100000
339,844 332,794 186,202
0
2015 2016 2017Jan-Jul
----- End of picture text -----

Antibody & Reagent Protein CTC instrument & kits Others

Antibody & Reagent Protein CTC instrument & kits Others

9

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

II. ABNOVA PRECISION MEDICINE

10

Abnova Core Competence in Precision Medicine A Vertically Integrated In Vitro Diagnostic Company

==> picture [794 x 290] intentionally omitted <==

----- Start of picture text -----

In Vitro Diagnostics
CytoQuest CR
System Integration CytoQuest Dx
GMP Bioreagents CytoBot
Instrumentations CytoAmp
Softwares CytoPrep
Antibody Bank
One Gene One Antibody
Resource & Support
----- End of picture text -----

11

Applications of Prenatal & Cancer Precision Medicine

Precision Medicine

Prenatal Prevention and Detection

Cancer Prevention and Detection

1. Amniocentesis (Invasive Prenatal Testing)

2. NIPT (Non-Invasive Prenatal Testing)

3. NIPD (Non invasive prenatal diagnosis)

4. Surrogate Diagnosis

5. Early Cancer

6. Cancer Relapse

7. Cancer Metastasis

8. Drug Guidance

9. Drug Resistance

10. Treatment Response

12

Tissue vs. Liquid Biopsy in Precision Medicine

Tissue Biopsy

Liquid Biopsy

• Invasive

• Non-invasive

• Painful

• Time saving

• Costly

• Real-time monitoring

• Takes time

• Regular monitoring

• Risky

==> picture [767 x 113] intentionally omitted <==

• Not enough tissue sample available

• Liquid Biopsy is � Not enough tumor tissue in the sample useful when there is: � A hard-to-reach tumor � Need for regular monitoring

13

Liquid Biopsy Applications in Precision Medicine

==> picture [794 x 121] intentionally omitted <==

CTC cfDNA Samples: 1. Blood 2. Urine 3. Other body fluid Exosome Detection Monitoring Surrogate Diagnosis Treatment Response Early Cancer Screening Drug Resistance Cancer Metastasis Cancer Relapse/Recurrence Drug Guidance

14

Abnova Precision Medicine Market Footprint in China, Japan & Taiwan

==> picture [642 x 160] intentionally omitted <==

Abnova Diagnostics (Tokyo)

Wellconn Genomics (Neihu)

Abnova Diagnostics (Dongguan) Wellconn Genomics (Dongguan)

15

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

III. ABNOVA DIAGNOSTICS (PRECISION MEDICINE PRODUCTS)

16

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

17

CytoQuest™ CR

Circulating Rare Cells Positive Enrichment & Retrieval System

Integrated System

• Buffer reservoir

• Fluidic pump

• SCx™spiral chamber

• Coupler

• HBx™micromixer

• Chip receptor

• TCx™thermal chuck

• Touch user interface

Antibody-based, cell capture

• Cell enumeration (CytoChipNano)

• Single cell isolation (CytoChipNano)

• Thermal cell release (CytoChipNano CR)

==> picture [794 x 120] intentionally omitted <==

18

CytoQuest CTC Bioreagents & Consumables

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

19

Unique Features of CytoQuest™ CR (1)

Capture & Recovery Rate of Spiked Cells in Whole Blood

Abnova Proprietary Cell-Surface Vimentin Antibody is Universal for CTC, EMT CTC, & CSC. Cell-Surface Vimentin is Specific for Cancer

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 263] intentionally omitted <==

----- Start of picture text -----

Abnova Proprietary EpCAM Antibody
Capture Rate Depends on Quality of Antibody
20
----- End of picture text -----

Unique Features of CytoQuest™ CR (2)

Viable CTC Capture in Diverse Cancers

Single Cell Isolation, Whole Genome Amplification (WGA), & Sequencing

==> picture [393 x 256] intentionally omitted <==

==> picture [228 x 138] intentionally omitted <==

On-Chip Molecular Analysis with FISH Probes

==> picture [168 x 136] intentionally omitted <==

==> picture [164 x 130] intentionally omitted <==

Viable CTC Release in Epithelial Cancers

==> picture [179 x 130] intentionally omitted <==

==> picture [179 x 130] intentionally omitted <==

21

CytoQuest™Dx Circulating Tumor Cell Positive Enrichment & Retrieval Automation

CytoQuest™ Dx Integration

• Total Solution Workstation

• XYZ Axis and 6 Axial Robotic Arm

• In-Process Controls & Sensors

• Intelligent Software Algorithm

• Self-Contained Modules

• RFID Consumable Tracking

• Clean Environment & HEPA Filter

CytoQuest™ Dx Advantages

• Precision, Accuracy, & Reproducibility

• High Throughput & Multi-Tasking

• Minimize Cross Contaminations

• Positive Selection Cell Isolation

==> picture [375 x 211] intentionally omitted <==

22

CytoBot™

Circulating Tumor Cell Negative Enrichment & Retrieval Automation

CytoBot™ Integration

• Total Solution Workstation

• Two 6 Axial Robotic Arms

• In Process Controls & Sensors

• Intelligent Software Algorithm

• Self-Contained Instruments

• Clean Environment & HEPA Filter

CytoBot™ Advantages

• Precision, Accuracy, & Reproducibility

• High Throughput & Multi-Tasking

• Minimize Cross Contaminations

• Negative Selection Cell Isolation

23

Proprietary Cell-Surface Vimentin (CSV) Antibody Universal CTC, EMT CTC, and CSC Antibody Cell-Surface Vimentin (not EpCAM) is Specific for Cancer

==> picture [215 x 10] intentionally omitted <==

----- Start of picture text -----

CSV+ CD133- CSV- CD133+
----- End of picture text -----

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

Figure 1. Analysis of colon cancer derived CSV+ CD45- CTCs from patient samples stained with EMT marker specific antibodies and anti-CSV monoclonal antibody, clone 84-1.[1]

Satelli A., et al., Clinical Cancer Research 2015; 21(4): 899-906. Mitra A., et al., International Journal of Cancer 2015; 137: 491-496.

Figure 2. A) Matrigel sphere formation assay of CSV+ CD133- and CSV- CD133+ cells isolated from hepatocellular carcinoma (HCC) at Day 7. Both spheres were stained with stem cell associated markers, Sox2 and Oct4A. B) CSV+ CD133- cells from HCC metastasize at a higher rate than CSV- CD133+ and CSV- CD133- cells.[2]

24

Proprietary Cell-Surface Vimentin (CSV) Antibody CTC Clinical Applicable for EMT and Mesenchymal Tumors

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

Cancers Epithelial Tumors

EMT Tumors Mesenchymal Tumors (Glioma, Sarcoma, Melanoma)

Curr Pathobiol Rep (2014) 2: 21-26.

25

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

26

Cell-Surface Vimentin (CSV) Publications

Author	Year	Journal
Izhar Singh Batth	2017	Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.
		Annals of Oncology
Arun Satelli	2016	Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
		Scientific Reports
Hyangsoon Noh	2016	Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells.
		Oncotarget
Abhisek Mitra	2015	EMT, CTCs and CSCs in tumor relapse and drug-resistance.
		Oncotarget
Arun Satelli	2015	Circulating Tumor Cell Enumeration with a Combination of Epithelial Cell Adhesion Molecule– and Cell-Surface Vimentin–Based Methods for Monitoring Breast Cancer Therapeutic Response.
		Clinical Chemistry
Abhisek Mitra	2014	Cell-surface Vimentin: A mislocalized protein for isolating csVimentin+CD133- novel stem-like hepatocellular carcinoma cells expressing EMT markers.
		International Journal of Cancer
Arun Satelli	2014	Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression.
		Clinical Cancer Research
Arun Satelli	2014	Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression.
		Clinical Cancer Research (Supplement)
Arun Satelli	2011	Vimentin as a potential molecular target in cancer therapy Or Vimentin, an overview and its potential as a molecular target for cancer therapy.
		Cellular and Molecular Life Sciences

27

CTC Clinical Applications Disease, Drug, & Surgery – Detection, Selection, & Monitoring

• Disease Detection & Monitoring

• Surrogate Diagnosis

• Early Cancer Detection

• Remission

• Relapse/Recurrence

• Metastasis

• Drug Selection & Monitoring

• Drug Guidance (Companion Diagnostics)

• Drug Response

• Drug Resistance

• Surgical Selection & Monitoring

• Surgical Guidance

• Surgical Response

• Surgical Resistance

28

Cancers & CSV CTC Clinical Applications (1)

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

29

Cancers & CSV CTC Clinical Applications (2)

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

30

Viable CTC Capture & Detection in Diverse Cancers (1)

Cell-Surface Vimentin as Novel EpithelialMesenchymal Transition and Cancer Stem Cell Biomarkers for Pancreatic Cancer Circulating Tumor Cells

EpCAM CK Positive Circulating Tumor Cells and B7-H3 CD105 Positive Cancer Stem Cells in Clear Cell Renal Cell Carcinoma

==> picture [377 x 177] intentionally omitted <==

Capture and Isolation of EpCAM and CD133 Positive Cells in Peripheral Blood of Non-Small Cell Lung Cancer Patients

==> picture [380 x 146] intentionally omitted <==

PSMA vs EpCAM Antibody Capture of Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Patient

==> picture [376 x 148] intentionally omitted <==

31

Viable CTC Capture & Detection in Diverse Cancers (2)

CDX2 Intestinal-Specific Expression in Circulating Tumor Cells of Metastatic Colorectal Adenocarcinoma Patient

Plastin-3 Transformed Circulating Tumor Cells in Hepatic Protal Vein of Pancreatic Cancer Patient for Predicting Liver Metastasis

Androgen Receptor Gene Amplification in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer Patient

Cell-Surface Vimentin Transformed EMT CTCs and CSCs in Metastatic Castration-Resistant Prostate Cancer

==> picture [385 x 87] intentionally omitted <==

==> picture [383 x 89] intentionally omitted <==

Cell-Surface Vimentin and Pan Cytokeratin Positive Circulating Tumor Cells in Pleural Effusion of Lung Adenocarcinoma Patient

==> picture [379 x 86] intentionally omitted <==

Antibodies Targeting ASGPR and PanCK for Capture and Identification of Circulating Hepatocellular Carcinoma Cells

==> picture [380 x 86] intentionally omitted <==

32

Viable CTC Capture & Detection in Diverse Cancers (3)

Circulating Epithelial Cells in Dialysis Patient with Antibodies Targeting HLA-G and PanCK for Acquired Cystic Kidney Disease Capture and Identification of Circulating Choriocarcinoma Cells

==> picture [794 x 121] intentionally omitted <==

Detection of Circulating Tumor Cells in Cholangiocarcinoma Patients

==> picture [381 x 84] intentionally omitted <==

Circulating Tumor Cells as Metastatic Biomarker in Oral Squamous Cell Carcinoma

==> picture [376 x 84] intentionally omitted <==

Prenatal Detection of Fetal Trophoblasts in Maternal Circulation

==> picture [378 x 86] intentionally omitted <==

33

On-Chip in situ mutaFISH™

Mutation Detection without Single Cell Isolation, PCR, WGA, NGS

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

34

mutaFISH™ Sensitivity Compared to dPCR, Nanostring, NGS

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

Nucleic Acid Research (2017) 45(8): e59.

35

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

III. WELLCONN DIAGNOSTICS (PRECISION MEDICINE SERVICES)

36

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

37

CytoQuest™ Workflow

==> picture [336 x 365] intentionally omitted <==

CytoQuest™ CR

==> picture [78 x 80] intentionally omitted <==

==> picture [267 x 365] intentionally omitted <==

38

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

39

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

40

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

41

==> picture [305 x 595] intentionally omitted <==

==> picture [360 x 270] intentionally omitted <==

42

Certified Medical Personnels

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

43

==> picture [794 x 358] intentionally omitted <==

----- Start of picture text -----

Man
Wellconn-QP01 組織與管理作業程序
Environment Mechanical
Wellconn-QP15 安全衛生與環境監控作 Wellconn-QP16 設備與試劑耗材管理作
業程序 業程序
懷慷醫事檢驗所
品質系統文件(4M1E)
----- End of picture text -----

Method

Wellconn-QP02 品質管理系統作業程序 Wellconn-QP03 文件管制作業程序 Wellconn SOP-C00 CytoQuest™CR作業標準 Wellconn SOP-C01 CytoQuest CR校正作業標準 Wellconn SOP-C02 CytoQuest CR 試劑檢驗作業 標準

Material

==> picture [268 x 61] intentionally omitted <==

----- Start of picture text -----

Wellconn-QP06 供應商評選作業程序
Wellconn-QP16 設備與試劑耗材管理作業程序
Wellconn-QP17 檢體採集與運送管理作業程序
Wellconn-QP18 檢體採集手冊
----- End of picture text -----

44

Wellconn Customers

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

45

Circulating Tumor Cell Service (1)

==> picture [745 x 130] intentionally omitted <==

==> picture [745 x 130] intentionally omitted <==

==> picture [745 x 129] intentionally omitted <==

46

Circulating Tumor Cell Service (2)

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

47

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

48

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

49